Lunai Bioworks Inc. (LNAI)
Automate Your Wheel Strategy on LNAI
With Tiblio's Option Bot, you can configure your own wheel strategy including LNAI - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LNAI
- Rev/Share 0.0
- Book/Share -1.3229
- PB -0.6646
- Debt/Equity -0.4765
- CurrentRatio 0.0359
- ROIC 16.9077
- MktCap 15648164.0
- FreeCF/Share -0.4879
- PFCF -1.9872
- PE -0.0797
- Debt/Assets 1.236
- DivYield 0
- ROE -2.8806
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Lunai Bioworks achieves complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models, marking a breakthrough in allogeneic cancer immunotherapy
Published: November 05, 2025 by: PRNewsWire
Sentiment: Neutral
Lunai Bioworks Announces Publication of Second-Generation Allogeneic Dendritic Cell Therapy Platform in the journal "Vaccines". LOS ANGELES , Nov. 5, 2025 /PRNewswire/ -- Lunai Bioworks (NASDAQ: LNAI), an AI-powered drug discovery and biodefense company, has announced a major scientific breakthrough: its next-generation immune cell therapy led to complete regression of both primary and metastatic pancreatic tumors in humanized mouse models.
Read More
Lunai Bioworks Harnesses AI and Zebrafish Data to Advance Early Detection of Neurotoxic Compounds
Published: October 30, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / October 30, 2025 / In the face of growing global concern over the potential use of chemical weapons such as the nerve agent Sarin, Lunai Bioworks Inc. (NASDAQ:LNAI) today announced promising early results from its AI-based platform designed to identify compounds that interact with acetylcholinesterase (AChE), the same molecular target affected by nerve agents. "This research brings us closer to a future where proactive, AI-powered screening can detect and evaluate neurotoxic compounds before they become threats," said David Weinstein, CEO of Lunai Bioworks.
Read More
Lunai Bioworks Regains Compliance with Nasdaq Minimum Bid Price Requirement
Published: October 16, 2025 by: Accesswire
Sentiment: Neutral
LOS ANGELES, CALIFORNIA / ACCESS Newswire / October 16, 2025 / Lunai Bioworks, Inc. (Nasdaq:LNAI), today announced that it has regained compliance with Nasdaq's minimum bid price requirement. On April 14, 2025, Nasdaq Staff notified the Company that its common stock had failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days, as required by Listing Rule 5550(a)(2).
Read More
Lunai Bioworks Launches AI-Powered Alzheimer's Disease Program, Expanding Neurodegenerative Pipeline
Published: October 06, 2025 by: Accesswire
Sentiment: Neutral
LOS ANGELES, CALIFORNIA / ACCESS Newswire / October 6, 2025 / Lunai Bioworks (Nasdaq:LNAI) today announced a major advance in Alzheimer's research: its AI platform, Augusta™, achieved up to a 35% improvement in diagnostic accuracy by combining MRI scans with genetic and metabolic data. The company is launching a preclinical Alzheimer's program to bring this technology closer to clinical use, a move that could enable earlier intervention for millions worldwide.
Read More
About Lunai Bioworks Inc. (LNAI)
- IPO Date 2025-09-30
- Website http://www.renovarogroup.com
- Industry Biotechnology
- CEO David Weinstein
- Employees 29